Overview

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects. This study is designed to address the relative potency question for the first time in the same.

Phase:

Phase 1

Details

Lead Sponsor:

Mirum Pharmaceuticals, Inc.
Shire

Treatments:

Bile Acids and Salts
Volixibat